FDA Requests Additional Information on AbbVie's Application for Neurotoxin
By Kelly Cloonan
The Food and Drug Administration requested further information regarding AbbVie's application for a neurotoxin aimed at facial aesthetics.
AbbVie said Thursday the FDA's complete response letter to its biologics license application for trenibotulinumtoxinE requested additional information about manufacturing processes. The letter didn't identify any safety or efficacy concerns for the neurotoxin, the company said.
AbbVie expects to submit a response in the coming months. The company said it believes trenibotulinumtoxinE has the potential to expand patients' options in facial aesthetics.
"Though disappointed, we remain confident in the strength and integrity of our application, and we are well positioned to respond to the agency's feedback promptly to support completion of the review," said Roopal Thakkar, executive vice president, research and development, chief scientific officer at AbbVie.
Regulatory reviews for the neurotoxin in other countries are ongoing and progressing as expected, AbbVie said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
April 23, 2026 17:07 ET (21:07 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
United States